Eloralintide and tirzepatide combined for weight loss in adults with obesity
Tests eloralintide with tirzepatide for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Key facts
- Where
- Bahía Blanca, Buenos Aires, Ciudad de Buenos Aires, Córdoba, Del Viso, Godoy Cruz, Granadero Baigorria, Junín, Mar del Plata, Mendoza, Rosario, SAN M. de Tucuman, and Santiago del Estero, ArgentinaSee the 20 sites
- Phase
- Phase 3
Where in Argentina
- Instituto de Investigaciones Clínicas Bahia BlancaBahía Blanca, ArgentinaNo longer taking part
- CEMEDICBuenos Aires, ArgentinaNo longer taking part
- Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaNo longer taking part
- Centro Médico ViamonteBuenos Aires, ArgentinaNo longer taking part
- Cicemo SrlBuenos Aires, ArgentinaNo longer taking part
- Consultorio Medico Investigador Principal Dr BesadaBuenos Aires, ArgentinaNo longer taking part
- DOLZ Investigación ClínicaBuenos Aires, ArgentinaNo longer taking part
- Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaNo longer taking part
- IDIM - Instituto de Investigaciones MetabólicasCiudad de Buenos Aires, ArgentinaNo longer taking part
- Centro Medico Privado San Vicente DiabetesCórdoba, ArgentinaNo longer taking part
- MICA - Medicina e Investigación CardiometabólicaDel Viso, ArgentinaNo longer taking part
- Hospital Español de MendozaGodoy Cruz, ArgentinaNo longer taking part
- Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaNo longer taking part
- CMD-Centro Médico y Diagnóstico por ImágenesJunín, ArgentinaNo longer taking part
- Centro de Investigaciones Medicas Mar Del PlataMar del Plata, ArgentinaNo longer taking part
- Instituto de Cardiología WolffMendoza, ArgentinaNo longer taking part
- Instituto Médico Catamarca IMECRosario, ArgentinaNo longer taking part
- Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención MedicaRosario, ArgentinaNo longer taking part
- Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaNo longer taking part
- Sanatorio NorteSantiago del Estero, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881432EU 2026-526047-34-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Inclusion: Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥35 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any glucose-lowering medication within 90 days of screening.